刘景晶查看源代码讨论查看历史
| 刘景晶 | |
|---|---|
|
中国药科大学生命科学与技术学院副院长 | |
| 出生 |
1957年2月 福建 |
| 逝世 | 2011年7月29号 |
| 国籍 | 中国 |
| 职业 | 教育科研工作者 |
刘景晶，1957年2月-2011年7月，福建人，博士，教授，博士生导师[1]，中国药科大学生命科学与技术学院副院长[2]，美国眼科学会会员。曾被评为江苏省"六大"人才高峰人选，江苏省"333"工程第二层次人选，校跨世纪学术带头人[3]。2011年7月29号底因肝癌病逝。
主要研究
(1)在美国North Texas大学医学中心做博士后工作期间，在世界上首次从人视网膜发现了一种新型血管内皮生长因子-VEGF183，基因序列首先在国际基因库登录，并于1999年在Invest Ophthalmol Vis Sci.以第一作者发表(IF5.2)。
(2)以刘景晶为主完成的抗癌药-门冬酰胺酶，已收载于2000年版中国药典，荣获江苏省科技进步二等奖(排名第一)。以刘景晶为主完成的"酶法生产丙氨酸"项目也在省内企业实现了产业化生产，获得国家医药总局科技进步二等奖;完成了"用基因工程菌酶法生产D-对羟基苯甘氨酸"通过了江苏省科技厅组织的专家鉴定(苏科鉴字[2002]第321号; 排名第一)。
(3) 在技术创新方面，在国内外首次提出了"微基因药学"的学科设想，沿该研究思路开展了与重大疾病相关的一系列微基因药学相关技术研究，完成了微基因药物制备技术平台研究的"863"项目，建立了"微基因药学"相关的技术平台，并被学校确立为"211"工程重点支持的研究方向。
(4) 建立的以微基因药物为研究方向的研究团队承担了多项国家"863"计划课题、国家自然科学基金课题和江苏省自然科学基金项目，研究方向主要有治疗糖尿病的重组人胰岛素类等肽类药物、抗肿瘤生长的核酸疫苗和蛋白质类疫苗、抗动脉粥样硬化蛋白质药物和疫苗、抗骨质疏松症的小肽类药物甲状旁腺素类似物等，研究经费达170万多元。
(5)申请并公开的国家专利25项;在国内外核心学术期刊上发表各类论文150多篇，其中SCI论文40多篇，多篇论文在J Immunol(IF 6.293)、J Biol Chem(IF 5.808)、Invest Ophthalmol Vis Sci(IF 5.2)Endocr Relat Cancer(IF 5.2)、Vaccine(IF 3.159)等国际著名学术杂志上刊登，影响因子超过90。
(6)在科研成果的转化方面，由刘景晶为主完成的抗癌药门冬酰胺酶已经在江苏省内企业――常州千红生化制药厂生产，产品已经在国内各个大医院使用，并已经出口到印度等国家，已经创造经济效益几千万元,该产品曾经获得江苏省科技进步二等奖;由刘景晶为主完成的"酶法生产丙氨酸"项目也在省内企业实现了产业化生产，获得原国家医药总局科技进步二等奖;完成了"用基因工程菌酶法生产D-对羟基苯甘氨酸"通过了江苏省科技厅组织的专家鉴定(排名第一)。
个人荣誉
曾多次承担国家"863"计划课题、国家自然科学基金课题，目前领导的团队仍有四项国家自然科学基金项目和两项省自然科学基金项目，研究经费共计140万多元。
学术论文
刘景晶教授近年发表的主要SCI论文
[1] Yong Lu, Didier Mekoo, OuyanKedong, XiangbingHu, Yanhua Liu, Ming Lin, Liang Jin, Rongyue Cao, Taiming Li, Zhang Yankai, Hao Fan and Liu Jingjing*.Strong humoral response elicited by a DNA vaccine targeting gastrin-releasing peptide with optimized adjuvants inhibits murine prostate carcinoma growth in vivo.Endocrine-Related Cancer.DOI: 10.1677/ERC-09-0058.
[2] L Yong, Z Huiyong, F Jing, W Huaqian, Y Kejun, Y Yanan, L Suli, W Xuejun, M Yuhan, C Rongyue, F Hao, L Taiming*, andL Jingjing*.Study on preparation and unique properties of a novel insulin analogue with N-terminal Arg-4, Pro-3, Lys-2, Pro-1extension at insulin B-chain.Regulatory Peptides, Oct 2009; 157(1-3): 92-8.
[3] Yong Lu, Jing Fang, KedongOuyang, Guojun Wu, Huiyong Zhang, Yanhua Liu, Yingying Chen, Ming Lin, Huaqian Wang, Liang Jin, Rongyue Cao, Rouel S. Roque, Li Zong, JingjingLiu,* and Taiming Li*. (Lu Yong and Fang Jing contributed equally to this paper). Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo. ClinVaccineImmunol, July 2009, p.1033-1039, Vol. 16, No. 7
[4] Y Lu, K Ouyang, J Fang, H Zhang, G Wu, Y Ma, Y Zhang, X Hu, L Jin, R Cao, H Fan, T Li, and J Liu*. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope, Vaccine, Aug 2009; 27(39): 5411-8.
[5]Jiao Feng, Yanhua Liu, Yun Xing, Huaqian Wang, Taiming Li, JingjingLiu, Hao Fan, Rongyue Cao *.A novel human parathyroid hormone (1-34) analog for the treatment of Osteoporosis. Peptides. DOI:10.1016/j.peptides.2009.02.013.
[6]Yunxiao, Sun; Zhufang, Li; Xin, Yang; Jun, Long; Qiyan, Xiong; Gaofu, Qi; Rongyue, Cao; Jie, Wu; Jingjing, Liu; Hao, Fan; Taiming, Li. Construction, Expression,Purification and Immunology Effect of an AntiatherosclerosisChimeric Enzyme Vaccine in Escherichia coli. [J]Protein & Peptide Letters, 2008, 15, 745-752
[7] QiyanXiong, Jianping Li, Liang Jin, JingjingLiu, Taiming Li*. Nasal mmunization with heat shock protein 65 attenuates atherosclerosis and reduces serum lipids in cholesterol-fed wild-type rabbits probably through different mechanisms. Immunology Letters.DOI:10.1016/j.imlet.2009.05.007.
[8] XiongQiyan, Jin Liang, Li Jianping, Fan Hao, Cao Rongyue, Wu Jie, Li Taiming and Liu Jingjing*. A Th2 immune shift to heat shock protein 65 fails to arrest atherosclerosis :Proatherogenic role of Th2-deviated Autoantibodies. Autoimmunity. DOI: 10.1080/08916930902887086.
[9] Liang J, Aihua Z, Yu W,JingjingL*.Enhanced Immunogenicity of Peptide P277 by Heat Shock Protein HSP65 Vector Carrying Tandem Repeats of P277 to Prevent Type 1 Diabetes in NOD Mice[J]. Exp ClinEndocrinolDiabetes. 2008;116:541-548.
[10]Guojun W, Wei G, Kedong O, Yi H, Yanfei X, Qingmei C, Yankai Z, Jie W, Hao F, Taiming L, JingjingL, Rongyue C. A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. EndocrRelatCancer, 2008,15(1):149-59
[11] Jin L, Zhu A, Wang Y, Chen Q, Xiong Q, Li J, Sun Y, Li T, Cao R, Wu J, Liu J. A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice. J Immunol, 2008,180(1):58-63
[12] Xu J, Zhu Z, Wu J, Liu W, Shen X, Zhang Y, Hu Z, Zhu D, Roque RS, Liu J. Immunization with a recombinant GnRH vaccine conjugated to heat shock protein 65 inhibits tumor growth in orthotopic prostate cancer mouse model. Cancer Lett, 2008,259(2):240-50
[13] Zhang Y, Xu J, Zhao R, Liu J. Wu J.Inhibition effects on liver tumors of BALB/c mice bearing H22 cells by immunization with a recombinant immunogen of GnRH linked to heat shock protein 65. Vaccine, 2007,25(39-40):6911-21
[14]Chunxiao W, JingjingL. Yire X, Min D, Zhaohui W, Gaofu Q, Xiangchun S, Xuejun W, Jie W, Taiming L. Study on preparation and activity of a novel recombinant human parathyroid hormone (1-34) analog with N-terminal Pro-Pro extension.RegulPept, 2007,141(1-3):35-43
[15] Jin L, Wang Y, Xiong Q, Chen Q, Li J, Zhu A, Cao R, Wu J, Liu J. Long-lasting specific antibodies against P277 induced by mucosal administration of P277 repeat sequences carried by Hsp65 in the absence of adjuvants.Vaccine, 2007,25 (11):2043-50
[16] Xu J, Zhu Z, Duan P, Li W, Zhang Y, Wu J, Hu Z, Roque RS,Liu J. Cloning, expression, and purification of a highly immunogenic recombinant gonadotropin-releasing hormone(GnRH) chimeric peptide. Protein ExprPurif, 2006,50(2):163-70
[17] Xu J, Li W, Wu J, Zhang Y, Zhu Z, Liu J, Hu Z. Stability of plasmid and expression of a recombinant gonadotropin-releasing hormone(GnRH) vaccine in Escherichia coli.ApplMicrobiolBiotechnol, 2006,73(4):780-8
[18] Yankai Z, Rong Y, Yi H, Wentao L, Rongyue C, Ming Y, Taiming L, JingjingL, Jie W. Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. BiochemBiophysRes Commun, 2006,345(4):1365-71
[19] Mao D, Kai G, Gaofu Q, Zheng Z, Li Z, Jie W, JingjingL, Rongyue C. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis.Vaccine, 2006,24(23):4942-50
[20] Gaofu Q, Rongyue C, Dan M, Xiuyun Z, Xuejun W, Jie W, JingjingL. Asparaginase display of human cholesteryl ester transfer protein(CETP) B cell epitopes for inducing high titers of anti-CETP antibodies in vivo. Protein PeptLett, 2006,13(2):149-54
[21] Tang SS, Du MH, Zhang XW, Zhang JH, Wu J, Mahanmad E, Liu JJ. A novel hGHRH analog and its comparative activity.Comb ChemHigh Throughput Screen, 2006,9(3):197-20
[22] Yi H, Rong Y, Yankai Z, Wentao L, Hongxia Z, Jie W, Rongyue C, Taiming L, JingjingL. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Vaccine, 2006,24(14):2575-84
[23] Jinshu X, JingjingL, Duan P, Zheng Z, Ding M, Jie W, Rongyue C, Zhuoyi H, Roque RS. A synthetic gonadotropin-releasing hormone(GnRH) vaccine for control of fertility and hormone dependent diseases without any adjuvant.Vaccine, 2005,23 (40):4834-43
[24] Gaofu Q, Jun L, Xiuyun Z, Wentao L, Jie W, JingjingL. Antibody against cholesteryl ester transfer protein(CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci, 2005,77(21):2690-70
[25] Gaofu Q, Jie L, Rongyue C, Xin Y, Dan M, Jie W, Xiangchun S, Qunwei X, Roque RS, Xiuyun Z, JingjingL. Asparaginase display of polypeptides in the periplasm of Escherichia coli: potential rapid pepscan technique for antigen epitope mapping. J ImmunolMethods, 2005,299(1-2):9-19
[26] Gaofu Q, Jun L, Xin Y, Wentao L, Jie W, Xiuyun Z, JingjingL. Vaccinating rabbits with a cholesteryl ester transfer protein(CETP) B-Cell epitope carried by heat shock protein-65(HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J CardiovascPharmacol, 2005,45(6):591-8
[27] Gaofu Q, Dan M, Jie W, Liao Z, Li Z, Roque RS, JingjingL. Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants. Vaccine, 2004,22(23-24):3187-94
[28] Jinshu X, JingjingL, Duan P, Zheng Z, Ding M, Jie W, Rongyue C, Zhuoyi H. The immunogenicity of recombinant and dimericgonadotrophin-releasing hormone vaccines incorporating a T-helper epitope and GnRH or repeated GnRH units.JImmunolMethods, 2004,289(1-2):111-22
[29]Gaofu Q, Jie W, Xin Y, Roque RS, JingjingL. Expressing and purifying an anti-atherosclerosis polypeptide vaccine in Escherichia coli. ProteinExprPurif, 2004,36(2):198-206
[30] Tang SS, Zhang JH, Du MH, Wu J, Liu JJ. Construction and activity of a novel GHRH analog, Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys. ActaPharmacolSin, 2004,25(11):1464-70
[31] Tang SS, Chen ZL, Liu JJ. Production and enhanced biological activity of a novel GHRH analog, hGHRH with an N-terminal Pro-Pro extension.Protein ExprPurif, 2004,34(2):296-301
[32] Evert BA, Salmon TB, Song B, JingjingL, Siede W, Doetsch PW. Spontaneous DNA damage in Saccharomycescerevisiae elicits phenotypic properties similar to cancer cells.J BiolChem, 2004,279(21):22585-94
[33] Yuehua L, Jing G, Kai F, Hongwei W, JingjingL. Left atrialmyxoma presenting with erythematousmacules and loss of memory. ClinExp Dermatol, 2003,28(4):383-6
[34] Zhang Y, Taiming L, Liu J. Low temperature and glucose enhanced T7 RNA polymerase-based plasmid stability for increasing expression of glucagon-like peptide-2 in Escherichia coli. Protein ExprPurif, 2003,29(1):132-9
[35] Tan S, Wu W, Liu J, Kong Y, Pu Y, Yuan R. Efficient expression and secretion of recombinant hirudin III in E. coli using the L-asparaginase II signal sequence. Protein ExprPurif, 2002,25(3):430-6
[36] Ming Xin, Yang Li, Lin Jie, Ding Min and JingjingLiu. An X-ProlylDipeptidylAminopeptidase from Lactococcuslactis: Cloning, Expression in Escherichia coli, and Application for Removal of N-Terminal Pro-Pro from Recombinant Proteins. Protein ExprPurif, 2002,2(3):530-8
[37] JingjingL, Srinivasan B, Roque RS. Ectodomain shedding of VEGF183, a novel isoform of vascular endothelial growth factor, promotes its mitogenic activity in vitro. Angiogenesis, 2001,4(2):103-12
[38]JingjingL, Srinivasan B, Bian X, Downey HF, Roque RS. Vascular endothelial growth factor is increased following coronary artery occlusion in the dog heart. Mol Cell Biochem, 2000,214(1-2):23-30
[39]JingjingL, Xue Y, Agarwal N, RoqueRSHumanMüller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest OphthalmolVis Sci, 1999,40(3):752-9
[40]Roque RS, Rosales AA, JingjingL, Agarwal N, Al-UbaidiMRRetina-derived microglial cells induce photoreceptor cell death in vitro. Brain Res, 1999,836 (1-2):110-9
[41]Harold J，Sheedlo，RaghuKrishnamoorthy，Tammy Nelson，NeerajAgarwal，Jingjing Liu，Rouel S. Roque，Robert J Retina-derived fetuin (RDF): Analysis by immunocytochemistry, reverse transcriptase-polymerase chain reaction and Southern blotCurrent Eye Research, 1999，19(6), 465-71
所建实验室
刘景晶教授建立的微基因药物实验室
刘景晶教授建立的实验室拥有HPLC，毛细管电泳，高速冷冻离心机，酶标仪，5L和50L的发酵罐等多台先进仪器。除了常规实验室以外，实验室还配备有专门的动物房和细胞房。目前刘老师领队的科研团队主要致力于核酸和多肽类疫苗的研发，包括动脉粥样硬化，糖尿病，肿瘤等相关疫苗和多肽类生物技术药物。实验室拥有二十多个从事分子、生化、免疫、药理的硕士和博士研究生。
微基因药物实验室与企业的成功合作
微基因药物实验室还与上海一就生物医药有限公司建立了长期的互助合作关系。
上海一就生物医药有限公司是一家致力于生物活性肽衍生肽开发和多肽表达技术研究的现代生物技术公司。公司根据现代药物研发的最新理念和技术，建立了生物活性肽高效表达和大规模制备技术平台。在生物活性肽衍生肽研究和生物活性肽高效率表达等方面处于领先水平。